Background: Improve the treatment quality might affect patients' efficacy and survival.
Methods: Five hundred thirty multiple myeloma patients treated in four hematological centers …

In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved
outcomes when added to the standard-of-care regimens. In a randomized trial, we tested …

Study Objective To compare the efficacy and safety of once‐weekly and twice‐weekly
bortezomib therapy in patients with hematologic malignancies. Design Meta‐analysis of 13 …

It is well-known that the tumor microenvironment (TME) plays an important role in the
regulation of tumor growth and the efficacy of anti-tumor therapies. Recent studies have …

Background Bortezomib‐related peripheral neuropathy (PN) affects a relevant proportion of
multiple myeloma (MM) patients treated with melphalan, prednisone, and bortezomib (VMP) …

Introduction: Limited data exist on interphase fluorescent in situ hybridization (iFISH)-based
survival outcomes in newly diagnosed multiple myeloma (NDMM) from India. Objectives: To …

Our study highlights that for patients with myeloma treated with the chemotherapy drug
bortezomib, the number of cycles of treatment received is an important predictor of survival …